Traws Pharma Stock Today
| TRAW Stock | 5.02 0.31 5.82% |
Performance0 of 100
| Odds Of DistressOver 85
|
Traws Pharma is selling for under 5.02 as of the 21st of December 2024; that is 5.82 percent decrease since the beginning of the trading day. The stock's lowest day price was 5.02. Traws Pharma has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Traws Pharma symbol was changed from ONTX on 3rd of April 2024. The performance scores are derived for the period starting the 22nd of October 2024 and ending today, the 21st of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 2nd of January 2001 | Category Healthcare | Classification Health Care |
Traws Pharma is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 25.31 M outstanding shares of which 7.71 K shares are at this time shorted by private and institutional investors with about 0.36 trading days to cover. More on Traws Pharma
Moving against Traws Stock
Traws Stock Highlights
| Older Symbol | ONTX | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CEO Director | Werner Cautreels | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Traws Pharma (TRAW) is traded on NASDAQ Exchange in USA. It is located in 12 Penns Trail, Newtown, PA, United States, 18940 and employs 17 people. Traws Pharma was previously known as Onconova Therapeutics and was traded on NASDAQ Exchange under the symbol ONTX. Traws Pharma is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 8.85 M. Traws Pharma conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 25.31 M outstanding shares of which 7.71 K shares are at this time shorted by private and institutional investors with about 0.36 trading days to cover.
Traws Pharma generates negative cash flow from operations
Check Traws Pharma Probability Of Bankruptcy
Ownership AllocationTraws Pharma shows a total of 25.31 Million outstanding shares. Traws Pharma has 14.62 % of its outstanding shares held by insiders and 11.4 % owned by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Traws Ownership Details
Traws Pharma Historical Income Statement
Traws Stock Against Markets
Traws Pharma Corporate Management
| Robert MD | Acting Officer | Profile | |
| Mark CPA | Chief Officer | Profile | |
| Victor MD | Chief Oncology | Profile | |
| Charles Pauza | Chief Virology | Profile |
Additional Tools for Traws Stock Analysis
When running Traws Pharma's price analysis, check to measure Traws Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Traws Pharma is operating at the current time. Most of Traws Pharma's value examination focuses on studying past and present price action to predict the probability of Traws Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Traws Pharma's price. Additionally, you may evaluate how the addition of Traws Pharma to your portfolios can decrease your overall portfolio volatility.